Open Access
ARTICLE
Leonard Lothstein*, Judith Soberman†, Deanna Parke*, Jatin Gandhi*, Trevor Sweatman‡, Tiffany Seagroves*
Oncology Research, Vol.28, No.5, pp. 451-465, 2020, DOI:10.3727/096504020X15898794315356
Abstract Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the
use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds.
Multidrug therapies achieve pathological cure rates of only 20–40%, a consequence of drug resistance and
cumulative dose limitations necessitated by the reversible cardiotoxic effects of drug therapy. Safer and more
effective treatments for TNBC are required to achieve durable therapeutic responses. This study describes the
mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary
TNBC. Pivarubicin directly activates PKCd, triggers rapid mitochondrial-dependent apoptosis, and circumvents resistance conferred by overexpression… More >
Open Access
ARTICLE
Dong Li*1, Fei-fan Sun*1, Dan Wang*1, Tao Wang*, Jing-jing Peng*, Jian-Qiong Feng*, Hua Li*,
Chao Wang†, Dai-jun Zhou*, Hong Luo*, Zeng-qiang Fu*, Tao Zhang*
Oncology Research, Vol.28, No.5, pp. 467-481, 2020, DOI:10.3727/096504020X15925659763817
Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma
(HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1
(PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it
has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However,
the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this
study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated
PD-L1 depletion attenuated drug resistance and suppressed the migration,… More >
Open Access
ARTICLE
Chenglin Qin*†, Linfang Jin*‡, Jia Li*§, Wenzhang Zha†, Huiming Ding†, Xiaorong Liu*¶, Xun Zhu*
Oncology Research, Vol.28, No.5, pp. 483-495, 2020, DOI:10.3727/096504020X15928179818438
Abstract Long intergenic nonprotein-coding RNA 02163 (LINC02163) has been reported to be upregulated and work
as an oncogene in gastric cancer. The aims of the present study were to determine the expression profile and
clinical value of LINC02163 in breast cancer. Additionally, the detailed functions of LINC02163 in breast
cancer were explored, and relevant molecular events were elucidated. In this study, LINC02163 was upregulated in breast cancer, and its expression level was closely associated with tumor size, lymph node metastasis,
and TNM stage. Patients with breast cancer presenting high LINC02163 expression exhibited shorter overall
survival than those presenting low LINC02163 expression.… More >
Open Access
ARTICLE
Yanhui Li*†, Su Dong*†, Arya Tamaskar†, Heather Wang†, Jing Zhao†, Haichun Ma*, Yutong Zhao†
Oncology Research, Vol.28, No.5, pp. 497-507, 2020, DOI:10.3727/096504020X15929939001042
Abstract Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 85% of all
lung carcinomas. The hepatocyte growth factor receptor (c-Met) has been considered as a potential therapeutic target for NSCLC. Proteasome inhibition induces cell apoptosis and has been used as a novel therapeutic
approach for treating diseases including NSCLC; however, the effects of different proteasome inhibitors on
NSCLC have not been fully investigated. The aim of this study is to determine a precise strategy for treating
NSCLC by targeting c-Met using different proteasome inhibitors. Three proteasome inhibitors, bortezomib,
MG132, and ONX 0914, were… More >
Open Access
ARTICLE
Junfeng Lu*, Zhongsong Zhao†, Yanhong Ma‡
Oncology Research, Vol.28, No.5, pp. 509-518, 2020, DOI:10.3727/096504020X15954139263808
Abstract The present study aimed to investigate the effect of miR-186 on proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) of hepatocellular carcinoma (HCC). In this work, miR-186 was downregulated in HCC tissues and cells, and low miR-186 level helped predict the occurrence of vascular invasion and
poor prognosis in patients with HCC. miR-186 overexpression inhibited cell proliferation and tumor growth
in nude mice, repressed migration and invasion abilities, and enhanced apoptosis in HCC cells. miR-186 also
retarded progression of EMT. miR-186 directly bound to the 3 -untranslated regions of cyclin-dependent kinase
6 (CDK6) to inhibit its expression. Overexpression of CDK6 markedly… More >
Open Access
ARTICLE
Jianing Yi*, Shuai Chen*, Pingyong Yi†, Jinlin Luo*, Meng Fang*, Yang Du*, Lianhong Zou*, Peizhi Fan*
Oncology Research, Vol.28, No.5, pp. 519-831, 2020, DOI:10.3727/096504020X15960154585410
Abstract 5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent for breast cancer. However, acquired chemoresistance leads to a loss of its efficacy; methods to reverse are urgently needed. Some studies have shown
that pyrotinib, an ErbB receptor tyrosine kinase inhibitor, is effective against HER2+
breast cancer. However,
whether pyrotinib sensitizes 5-FU-resistant breast cancer cells to 5-FU is unknown. We hypothesized that the
combination of pyrotinib and 5-FU would show synergistic antitumor activity, and pyrotinib could reverse
5-FU resistance in HER2+
breast cancer cells in vitro and in vivo. Our data showed that pyrotinib inhibited
the growth of 5-FU-resistant SKBR-3/FU and MDA-MB-453/FU… More >
Open Access
REVIEW
Qie Guo*, Xiao Li*, Meng-Na Cui*, Jia-Lin Sun*, Hong-Yan Ji*, Bei-Bei Ni*, Mei-Xing Yan†
Oncology Research, Vol.28, No.5, pp. 533-540, 2020, DOI:10.3727/096504020X15919605976853
Abstract Cancer is one of the most serious diseases that are harmful to human health. Systemic chemotherapy is an optimal therapeutic strategy for the treatment of cancer, but great difficulty has been encountered in its administration in the form of multidrug resistance (MDR). As an enzyme on the outer cell surface, CD13 is documented
to be involved in the MDR development of tumor cells. In this review, we will focus on the role of CD13 in
MDR generation based on the current evidence. More >
Open Access
REVIEW
Kazuo Umezawa*, Andrzej Breborowicz†, Shamil Gantsev‡
Oncology Research, Vol.28, No.5, pp. 541-550, 2020, DOI:10.3727/096504020X15929100013698
Abstract There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic
diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF- B inhibitor named dehydroxymethylepoxyquinomicin (DHMEQ) was discovered in
2000. This compound was designed based on the structure of epoxyquinomicin isolated from a microorganism.
It was shown to be a specific inhibitor that directly binds to and inactivates NF- B components. Until now,
DHMEQ has been used by many scientists in the world to suppress animal models of cancer and… More >
Open Access
ERRATUM
Jing Zeng*1, Tianping Du†1, Yafeng Song‡, Yan Gao‡, Fuyan Li‡, Ruimin Wu‡, Yijia Chen‡, Wei Li‡, Hong Zhou‡, Yi Yang‡, Zhijun Pei‡
Oncology Research, Vol.28, No.5, pp. 551-552, 2020, DOI:10.3727/096504020X16032056440085
Abstract Long noncoding RNA (lncRNA) colon cancer-associated transcript 2 (CCAT2) has been demonstrated to play
an important role in diverse tumorigenesis. However, the biological function of lncRNAs in glioma is still
unknown. In this study, we found that lncRNA CCAT2 was overexpressed in glioma tissues and cell lines and
associated with tumor grade and size. Furthermore, patients with high levels of lncRNA CCAT2 had poorer
survival than those with lower levels of lncRNA CCAT2. Knocking down lncRNA CCAT2 expression significantly suppressed the glioma cell growth, migration, and invasion, as well as induced early apoptosis of glioma
cells in vitro. Moreover, lncRNA… More >
Open Access
ERRATUM
Fen Liu*†, Shaojun Liu*, Feiyan Ai*†, Decai Zhang*†, Zhiming Xiao*, Xinmin Nie‡, Yunfeng Fu§
Oncology Research, Vol.28, No.5, pp. 553-557, 2020, DOI:10.3727/096504020X16032056440094
Abstract Colorectal cancer (CRC) is one of the most common malignancies in the world, with a high incidence and a
high mortality. However, the pathogenesis of CRC carcinogenesis is still unexplored. In this study, we investigated the role of miR-107 in the regulation of CRC cell proliferation and apoptosis. First, the expression of
miR-107 was observed to be aberrantly increased in human CRC tumor tissues and cell lines when compared to
the colonic control tissues and colon epithelial cells. Further study showed that the proliferative and apoptotic
capacities of human CRC SW480 and LoVo cells were aberrantly regulated by miR-107. The… More >
Open Access
ERRATUM
Kairui Liu*, Xiaolin Wu*, Xian Zang†, Zejian Huang*, Zeyu Lin‡, Wenliang Tan*, Xiang Wu*, Wenrou Hu*, Baoqi Li*, Lei Zhang*
Oncology Research, Vol.28, No.5, pp. 559-560, 2020, DOI:10.3727/096504020X16032056440102
Abstract Overexpression of the tumor necrosis factor receptor-associated factor 4 (TRAF4) has been detected in many
cancer types and is considered to foster tumor progression. However, the role of TRAF4 in hepatocellular carcinoma (HCC) remains elusive. In this study, we found that TRAF4 was highly expressed in HCC cell lines and
HCC tissues compared with normal liver cell lines and adjacent noncancerous tissues. TRAF4 overexpression
in HCC tissues was correlated with tumor quantity and vascular invasion. In vitro studies showed that TRAF4
was associated with HCC cell migration and invasion. An in vivo study verified that TRAF4 overexpression facilitated metastasis in… More >
Login
Register
Submit a Paper
Propose a Special lssue